My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.700 +0.140 (+2.52%)

Streaming Delayed Price Updated: 12:45 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

August 29, 2025

Via Benzinga

This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday ↗

August 29, 2025

Via Benzinga

This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 28, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Vir Biotechnology ↗

May 06, 2025

Via Benzinga

5 Analysts Have This To Say About Vir Biotechnology ↗

April 17, 2025

Via Benzinga

7 Analysts Have This To Say About Vir Biotechnology ↗

February 28, 2025

Via Benzinga

This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

August 28, 2025

Via Benzinga

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 27, 2025

Via Benzinga

Vir (VIR) Q2 Revenue Drops 61% ↗

August 07, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment ↗

January 08, 2025

The company is working to engage the immune system to attack cancer cells.

Via Investor's Business Daily

Where Vir Biotechnology Stands With Analysts ↗

July 11, 2025

Via Benzinga

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

May 22, 2025

Via Benzinga

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 12, 2025

Via Benzinga

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why ↗

January 10, 2025

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 08, 2025

Via Benzinga

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why ↗

January 08, 2025

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Via Benzinga

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday ↗

January 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 03, 2024

Via Benzinga

AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗

December 03, 2024

Via Benzinga

Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗

December 03, 2024

All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.

Via Investor's Business Daily

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗

December 03, 2024

Via Benzinga

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? ↗

November 15, 2024

Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.

Via Benzinga

What You Missed On Wall Street This Past Friday ↗

November 03, 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.